Health
Sinopharm’s potential Covid-19 vaccine triggers antibodies in clinical trials – PharmaLive
A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The shot did not cause any serious side effects, according to a paper published on Thursday in the Journal of the American Medical Association (JAMA) by scientists who are part of Sinopharm and other China-based disease control authorities and research institutes.
The results were based on data from 320 healthy adults in Phase 1 and 2 trials.
The candidate triggered robust antibody responses in inoculated people, but it remained unknown if that was sufficient to prevent COVID-19 infection, res…
-
Noosa News20 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News18 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
Noosa News18 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
Noosa News19 hours agoGood character references restricted in rape cases in Queensland